Correction of dismetabolic manifestations in perimenopausal and early postmenopausal women with fibrocystic disease


  • І. Т. Кишакевич Ivano-Frankivsk Medical University, Ukraine
  • Р. С. Конар Uzhgorod Municipal Polyclinic, Ukraine



perimenopause, fibrocystic breast changes, normomens


In 20% women in perimenopause occurs such the pathology of breast as fibrocystic breast disease.

The aim of study was to investigate the effectiveness and impact of the normomens drug on dysmetabolic disorders in women during perimenopause and early menopause on the background of fibrocystic breast changes.

There were 50 premenopausal women aged 43–48 years under supervision with dysmetabolic changes. Women were divided into two groups depending on condition and structure of mammary glands – 25 women with breast pathology as fibrocystic changes (group I), 25 women with no pathological changes in the mammary glands (group II).

To correct dismetabolic disorders background fibrocystic breast changes the phytopreparation normomens was used for 6 months.

The results showed a significant decrease in the psycho-emotional symptoms severity of climacteric syndrome, in some patients was restoration of regular menstrual periods, reduced the frequency and intensity of breast pain, women noted sleep improvement and a feeling of peace, comfort, weight reduction. In the breast after 3 months therapy in the dynamics ultrasound examination showed a decrease of the breast tissue density, after 6 months therapy it was reduction of the cysts diameter and number.

Thus, the proposed complex therapy with phytopreparation normomens showed good effect (treatment efficacy amounted to 89.7% of cases) for correction of metabolic disorders, mental and emotional state, and structural changes in the mammary glands, proves multivalent effect of the drug and makes it possible to use it as an alternative to hormone replacement therapy in perimenopause and early menopause. Normomens use allows not only to the prevention of breast cancer, but also improves the comfort and quality of patients’ life during premenopause and early menopause.

Author Biographies

І. Т. Кишакевич, Ivano-Frankivsk Medical University

MD, professor, Obstetrics and Gynecology Department

Р. С. Конар, Uzhgorod Municipal Polyclinic

PhD, oncologist, mammologist


  1. Arkov, V.V. Complex reconstructive correction of psycho-vegetative syndrome manifestations by physical factors and autogenous training: dissertation thesis for the PhD degree: spec. 14.00.01 “Obstetrics and Gynecology”. Moscow (2003): 25 p.
  2. Butrova, S.A. “Metabolic syndrome: pathogenesis, clinical features, diagnosis, treatment approaches.” Russian Medical Journal 9.2 (2011): 56–61.
  3. Popov, A.A., Izmozherova, N.V., Andreev, A.N., et al. “Depressive disorders in women with menopausal syndrome.” Reproduction Problems 1 (2010): 17–18.
  4. Zotov, A.S., Belik, E.O. Mastitis and breast cancer. Moscow. MEDpress-inform (2005): 112 p.
  5. Klimova, I.V., Breusenko, V.G. “Uterus and ovaries involutive changes in healthy postmenopausal women.” Russian Journal of Obstetrician- Gynecologist 2 (2012): 10–15.
  6. Campbell, S., Mong, E. Gynecology by ten teachers. Moscow. MIA (2013): 328 p.
  7. Letyagin, V.P., Vysotskaya, I.V., Kim, E.A. “Risk factors for breast cancer.” Mammalogy 4 (2006): 10–12.
  8. Liubota, R.V., Zotov, A.S., Vereshchako, R.I., Liubota I.I. Metabolic syndrome and breast cancer: Guidelines for physicians. Kyiv. Zaslavskyi A.Y. (2016): 62 p.
  9. Solovyova, A.D., Smetnik, V.P., Tatevosyan, A.G. “Correction of psycho-vegetative disorders in patients with climacteric syndrome.” In: Guidelines on menopause. Moscow. MIA (2011): 384–404.
  10. Tatarchuk, T.F. “Effectiveness of drugs with dopaminergic effects in the treatment of dyshormonal stress-induced pathology.” Reproductive Endocrinology 3.11 (2013): 90–94.
  11. Chistyakov, S.S. “Fibrous-cystic disease and benign tumors of the mammary glands.” In: Clinical mammalogy. Current status of the problem. Ed. by S.S. Chistyakov, E.B. Kampova-Polevaya. Moscow. GEOTAR-Media (2006): 116–143.
  12. Black, D.M., Steinbuch, M., Palermo, L., et al. “An assessment toot for predicting fracture risk in postmenopausal women.” Osteoporos Int 12 (2011): 519–28.
  13. Barrnes, S. “Phytoestrogen and breast cancer.” Bailliere’s Clin Endocrinol Metab 12 (2010): 559–79.
  14. Seidlova-Wuttke, D., Jarry, H., Viereck, V., et al. “Cimicifuga racemosa: a selective estrogen receptor modulator?” In: Midlife Health-Current Concepts and Challenges. Amsterdam. Elsevier (2011): 23–9.
  15. Dimmock, P.W. “Efficacy of selective serotonin–reuptake inhibitors in premenstrual syndrome: a systematic review.” Lancet 356 (2011): 1131–6.
  16. Diwanay, S., Chitre, D., Patwardhan, B. “Immunoprotection by botanical drugs in cancer chemotherapy.” J Ethnopharmacol 90 (2004): 49–55.
  17. Kumar, G.S., Jayaveera, K.N., Kumar, С.K.A., et al. “Antimicrobial effects of Indian medicinal plants against acne inducing bacteria.” Trop J Pharm Res 6 (2007): 717–23.
  18. Vidyasagar, G.M., Murthy, S.M. “Siddalinga Ethnomedicinal plants used to treat menstrual disorders by tribal people in Bellary district of Karnataka.” India IJPLS 3 (2012): 1871–6.
  19. Raju J., Patlolla M. R., Swamy M. V., et al. “Diosgenin, a steroid saponin of Trigonella foenum graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells.” Cancer Epidemiology Biomarkers and Prevention 13.8 (2004): 1392–98.



How to Cite

Кишакевич, І. Т., & Конар, Р. С. (2016). Correction of dismetabolic manifestations in perimenopausal and early postmenopausal women with fibrocystic disease. REPRODUCTIVE ENDOCRINOLOGY, (30), 82–86.



Management of menopause